{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:19:42Z","timestamp":1794737982243,"version":"4.9.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.beha.2024.101566","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:19:34Z","timestamp":1721866774000},"page":"101566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Allogeneic \u201cOff-the-Shelf\u201d CAR T cells: Challenges and advances"],"prefix":"10.1016","volume":"37","author":[{"given":"Sophia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel R.M.","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.beha.2024.101566_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2024.101566_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beha.2024.101566_bib3","article-title":"Allogeneic CAR cell therapy-more than a pipe dream","volume":"11","author":"Caldwell","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2024.101566_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.beha.2024.101566_bib5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.beha.2024.101566_bib6","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beha.2017.09.003","article-title":"Which factors influence the development of GVHD in HLA-matched or mismatched transplants?","volume":"30","author":"Petersdorf","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"303","key":"10.1016\/j.beha.2024.101566_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.beha.2024.101566_bib9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.beha.2024.101566_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","article-title":"Genome-edited allogeneic donor \"universal\" chimeric antigen receptor T cells","volume":"141","author":"Qasim","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jtct.2022.12.027","article-title":"Unrelated stem cell donor HLA match likelihood in the US registry incorporating HLA-DPB1 permissive mismatching","volume":"29","author":"Gragert","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.beha.2024.101566_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5030035","article-title":"Role of \u03b1\u03b2 T cell depletion in prevention of graft versus host disease","volume":"5","author":"Abdelhakim","year":"2017","journal-title":"Biomedicines"},{"issue":"24","key":"10.1016\/j.beha.2024.101566_bib13","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2024.101566_bib14","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \"Off-the-Shelf\" adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.beha.2024.101566_bib15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.beha.2024.101566_bib16","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.beha.2024.101566_bib17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol Ther"},{"issue":"7643","key":"10.1016\/j.beha.2024.101566_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"10266","key":"10.1016\/j.beha.2024.101566_bib20","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.beha.2024.101566_bib21","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.beha.2024.101566_bib22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.beha.2024.101566_bib23","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"668","key":"10.1016\/j.beha.2024.101566_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.beha.2024.101566_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1399-0039.1978.tb01233.x","article-title":"The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin","volume":"11","author":"Arce-Gomez","year":"1978","journal-title":"Tissue Antigens"},{"issue":"6307","key":"10.1016\/j.beha.2024.101566_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/349329a0","article-title":"Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice","volume":"349","author":"Bix","year":"1991","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.beha.2024.101566_bib27","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.beha.2024.101566_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.811200","article-title":"The human leukocyte antigen G as an immune escape mechanism and novel therapeutic target in urological tumors","volume":"13","author":"Jasinski-Bergner","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.beha.2024.101566_bib29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4049\/jimmunol.168.2.763","article-title":"Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III","volume":"168","author":"Holling","year":"2002","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.beha.2024.101566_bib30","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"7","key":"10.1016\/j.beha.2024.101566_bib31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to Be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.beha.2024.101566_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2005","journal-title":"Trends Immunol"},{"issue":"9","key":"10.1016\/j.beha.2024.101566_bib33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.beha.2024.101566_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1479-5876-12-45","article-title":"Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells","volume":"12","author":"Wilhelm","year":"2014","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.beha.2024.101566_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.beha.2024.101566_bib36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-Delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.beha.2024.101566_bib37","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1038\/s41467-023-42619-2","article-title":"Unlocking the potential of allogeneic V\u03b42 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR\/IL-15 engineering","volume":"14","author":"Lee","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.beha.2024.101566_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunology"},{"issue":"8","key":"10.1016\/j.beha.2024.101566_bib39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2022016202","article-title":"Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies","volume":"141","author":"Quach","year":"2023","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2024.101566_bib40","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2024.101566_bib41","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.beha.2024.101566_bib42","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2024.101566_bib43","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.beha.2024.101566_bib44","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-Specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"issue":"17","key":"10.1016\/j.beha.2024.101566_bib45","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2024.101566_bib46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.coi.2008.03.018","article-title":"CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system","volume":"20","author":"Matsuda","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"21","key":"10.1016\/j.beha.2024.101566_bib47","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","article-title":"Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Chaidos","year":"2012","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.beha.2024.101566_bib48","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","article-title":"CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells","volume":"124","author":"Schneidawind","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib49","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/leu.2016.281","article-title":"Pre-transplant donor CD4(-) invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease","volume":"31","author":"Rubio","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib50","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.beha.2024.101566_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"23","key":"10.1016\/j.beha.2024.101566_bib52","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.beha.2024.101566_bib53","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.beha.2024.101566_bib54","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2023019604","article-title":"Introduction to a review series on banked allogeneic immune effector cells","volume":"141","author":"Heslop","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2024.101566_bib55","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2024.101566_bib56","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nmeth.1591","article-title":"A more efficient method to generate integration-free human iPS cells","volume":"8","author":"Okita","year":"2011","journal-title":"Nat Methods"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.beha.2024.101566_bib58","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"10","key":"10.1016\/j.beha.2024.101566_bib59","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.beha.2024.101566_bib60","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","article-title":"Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T cells from T-cell-derived induced pluripotent stem cells","volume":"6","author":"van der Stegen","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"7","key":"10.1016\/j.beha.2024.101566_bib61","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1470-2045(10)70127-3","article-title":"Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis","volume":"11","author":"Eapen","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beha.2024.101566_bib62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/trf.14365","article-title":"Cord blood-derived T cells allow the generation of a more na\u00efve tumor-reactive cytotoxic T-cell phenotype","volume":"58","author":"Kwoczek","year":"2018","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.beha.2024.101566_bib63","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V94.9.3101","article-title":"Reduced NFAT1 protein expression in human umbilical cord blood T lymphocytes","volume":"94","author":"Kadereit","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101566_bib64","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2172-8-18","article-title":"Cytokine profiles of cord and adult blood leukocytes: differences in expression are due to differences in expression and activation of transcription factors","volume":"8","author":"Nitsche","year":"2007","journal-title":"BMC Immunol"},{"key":"10.1016\/j.beha.2024.101566_bib65","article-title":"Umbilical cord blood: a promising source for allogeneic CAR-T cells","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.beha.2024.101566_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133168","article-title":"Umbilical cord blood as a source of less differentiated T cells to produce CD123 CAR-T cells","volume":"14","author":"Ca\u00ebl","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.beha.2024.101566_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1139482","article-title":"Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.beha.2024.101566_bib68","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1283460","article-title":"Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR\/CD3 receptor and exhibit specific antitumor capacities","volume":"6","author":"Van Caeneghem","year":"2017","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib69","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","article-title":"New cell sources for T cell engineering and adoptive immunotherapy","volume":"16","author":"Themeli","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10.1016\/j.beha.2024.101566_bib70","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nm1463","article-title":"Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Zakrzewski","year":"2006","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib71","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nbt1395","article-title":"Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","volume":"26","author":"Zakrzewski","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.beha.2024.101566_bib72","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41423-021-00706-8","article-title":"A DL-4- and TNF\u03b1-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors","volume":"18","author":"Moirangthem","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"13","key":"10.1016\/j.beha.2024.101566_bib73","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.22.01229","article-title":"Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation","volume":"41","author":"Crivello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2024.101566_bib74","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood-2017-03-742346","article-title":"HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities","volume":"130","author":"Fleischhauer","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2024.101566_bib75","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","article-title":"Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study","volume":"13","author":"Fleischhauer","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.beha.2024.101566_bib76","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1500140","article-title":"High HLA-DP expression and graft-versus-host disease","volume":"373","author":"Petersdorf","year":"2015","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib77","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2021-146038","article-title":"ALPHA study: ALLO-501 produced deep and durable responses in patients with relapsed\/refractory non-hodgkin's lymphoma comparable to autologous CAR T","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib78","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2021-146045","article-title":"ALPHA2 study: ALLO-501A allogeneic CAR T in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing","volume":"138","author":"Lekakis","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2024.101566_bib79","first-page":"2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"Locke","year":"2023","journal-title":"J Clin Orthod"},{"issue":"15_suppl","key":"10.1016\/j.beha.2024.101566_bib80","first-page":"7516","article-title":"Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed\/refractory (r\/r) CD19+ NHL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Orthod"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib81","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1182\/blood-2022-168128","article-title":"A first-in-human phase 1, multicenter, open-label study of CB-010, a next-generation CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout, in patients with relapsed\/refractory B cell non-hodgkin lymphoma (ANTLER study)","volume":"140","author":"O'Brien","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib82","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 allogeneic CRISPR-cas9-engineered CAR T cells in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"issue":"7_Supplement","key":"10.1016\/j.beha.2024.101566_bib83","doi-asserted-by":"crossref","first-page":"ND02","DOI":"10.1158\/1538-7445.AM2023-ND02","article-title":"Abstract ND02: CTX112 and CTX131: next-generation CRISPR\/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors","volume":"83","author":"Terrett","year":"2023","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib84","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1182\/blood-2022-167194","article-title":"Interim phase I clinical data of ft819-101, a study of the first-ever, off-the-shelf, iPSC-derived TCR-less CD19 CAR T-cell therapy for patients with relapsed\/refractory B-cell malignancies","volume":"140","author":"Mehta","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2024.101566_bib85","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","article-title":"Off-the-Shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies. Transplantation and cellular therapy","volume":"30","author":"Ramos","year":"2024","journal-title":"Official Publication of the American Society for Transplantation and Cellular Therapy"},{"key":"10.1016\/j.beha.2024.101566_bib86","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/01.HS9.0000844368.41871.e3","article-title":"P370: early results of a safety and efficacy study of allogeneic TRUUCAR\u2122 GC502 in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-all)","volume":"6","author":"Li","year":"2022","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib87","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood-2023-178723","article-title":"Phase 1\/2 dose-escalation\/dose-expansion study of anti-CD7 allogeneic CAR-T cells (Wu-CART-007) in relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (T-ALL\/LBL)","volume":"142","author":"Ghobadi","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2024.101566_bib88","first-page":"7509","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies","volume":"40","author":"Neelapu","year":"2022","journal-title":"J Clin Orthod"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib89","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood-2023-186570","article-title":"Preliminary results of nathali-01: a first-in-human phase I\/IIa study of UCART20x22, a dual allogeneic CAR-T cell product targeting CD20 and CD22, in relapsed or refractory (R\/R) non-hodgkin lymphoma (nhl)","volume":"142","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.beha.2024.101566_bib90","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000972520.32337.3f","article-title":"P1408: updated results of the phase I BALLI-01 trial of UCART22, an ANTI-CD22 allogeneic car-t cell product, in patients with relapsed or refractory (R\/R) CD22+ B-cell acute lymphoblastic leukemia (B-all)","volume":"7","author":"Boissel","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib91","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2022-160244","article-title":"CD30.CAR-Modified epstein-barr virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective off-the-shelf therapy for patients with CD30-positive lymphoma","volume":"140","author":"Quach","year":"2022","journal-title":"Blood"},{"issue":"8_Supplement","key":"10.1016\/j.beha.2024.101566_bib92","doi-asserted-by":"crossref","first-page":"CT011","DOI":"10.1158\/1538-7445.AM2023-CT011","article-title":"Abstract CT011: a phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)","volume":"83","author":"Srour","year":"2023","journal-title":"Cancer Res"},{"issue":"7_Supplement","key":"10.1016\/j.beha.2024.101566_bib93","doi-asserted-by":"crossref","first-page":"CT002","DOI":"10.1158\/1538-7445.AM2024-CT002","article-title":"Abstract CT002: CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: long-term follow-up and translational data from the phase 1 COBALT-RCC study","volume":"84","author":"Pal","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2024.101566_bib94","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: the cobalt-lym study of CTX130: a phase 1 dose escalation study of CD70-TARGETED allogeneic CRISPR-CAS9\u2013ENGINEERED CAR T cells in patients with relapsed\/refractory (R\/R) t-cell malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib95","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1.2, an anti-cd123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"issue":"7_Supplement","key":"10.1016\/j.beha.2024.101566_bib96","doi-asserted-by":"crossref","first-page":"CT071","DOI":"10.1158\/1538-7445.AM2024-CT071","volume":"84","author":"Dholaria","year":"2024","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2024.101566_bib97","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2021-147738","article-title":"Immunicy-1: targeting BCMA with cyad-211 to establish proof of concept of an shRNA-based allogeneic CAR T cell therapy platform","volume":"138","author":"Al-Homsi","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.beha.2024.101566_bib98","first-page":"TPS6586","article-title":"A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed\/refractory acute myeloid leukemia (AMpLify)","volume":"42","author":"Daver","year":"2024","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.beha.2024.101566_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100151","article-title":"46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors","volume":"16","author":"Oh","year":"2022","journal-title":"Immuno-Oncology and Technology"},{"issue":"3_suppl","key":"10.1016\/j.beha.2024.101566_bib100","first-page":"74","article-title":"Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC","volume":"39","author":"Prenen","year":"2021","journal-title":"J Clin Orthod"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262400032X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169262400032X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T16:01:11Z","timestamp":1728576071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169262400032X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S152169262400032X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2024.101566","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic \u201cOff-the-Shelf\u201d CAR T cells: Challenges and advances","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2024.101566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101566"}}